scholarly journals Bleeding predictors in acute coronary syndrome: does the age or clinical presentation matters?

2021 ◽  
Vol 10 (Supplement_1) ◽  
Author(s):  
C Marques Pires ◽  
I Campos ◽  
P Medeiros ◽  
R Flores ◽  
F Mane ◽  
...  

Abstract Funding Acknowledgements Type of funding sources: None. INTRODUCTION Bleeding is a quite common non-cardiac complication of acute coronary syndrome (ACS) and is associated with a negative prognosis impact. AIMS To determine the predictors of inhospital major bleeding (IHMB) in ACS and to evaluate whether they differ according to age and clinical presentation. METHODS A multicentric retrospective study which analysed 25524 patients(pts) with ACS, 25141 without and 383 with IHMB. By multivariate analysis, we determined IHMB predictors and evaluated the differences between age groups (<80 years; ≥80 years) and clinical presentation- ST elevation myocardial infarction (STEMI) or non-ST elevation ACS (NSTEACS). RESULTS By multivariate analysis we found 15 significant IHMB predictors (pvalue < 0,05): age≥75years, hypertension, previous angina, pulmonary disease, previous bleeding, atypical presentation (without pain), cardiac arrest, admission heart rate (HR)>100bpm, Killip4 at admission, ST-elevation, admission haemoglobin (Hb)<10g/dL, aspirin or Vitamin K antagonist (VKA) or ivabradine as previous medication and  glycoprotein IIb/IIIa inhibitors (GPIIb/IIIa) use. Then, we made a sub-analysis in STEMI pts which revealed that IHMB predictors of pts <80 years were: female gender, age≥75years, chronic kidney disease (CKD), active neoplasm, previous bleeding, atypical presentation, cardiac arrest, admission HR > 100bpm, Killip IV on admission and GPIIb/IIIa use. By contrast, IHMB predictors of pts with ≥80 years were: valvular disease, atypical presentation, aspirin as previous medication and GPIIb/IIIa use. Finally, we made a sub-analysis in NSTACS pts which revealed that IHMB predictors of pts <80years were: previous angina, CKD, previous bleeding, cardiac arrest, Killip≥2 at admission, admission Hb < 10g/dL and VKA as previous medication. Conversely, IHMB predictors of pts with ≥80 years were previous bleeding, cardiac arrest and absence of normal QRS. In addition, by multivariate analysis we found that IHMB had an impact on inhospital mortality (OR = 2,2;pvalue < 0,001), however, by Cox regression there wasn’t an impact on 1-year mortality. CONCLUSION This study suggests that IHMB has impact on inhospital mortality and that its predictors differ with age and clinical presentation. The most powerful predictor was previous bleeding. Considering the importance of IHMB, increased efforts are needed to tailor antithrombotic therapy according to age, renal function and other comorbidities.

Cardiology ◽  
2021 ◽  
Author(s):  
Ran Eliaz ◽  
Bethlehem Mengesha ◽  
Tal Ovdat ◽  
Zaza Iakobishvili ◽  
David Hasdai ◽  
...  

Introduction: We aimed to compare the outcomes of ACS (acute coronary syndrome) patients undergoing in-hospital PCI (percutaneous coronary intervention) treated with prasugrel versus ticagrelor. Methods: Among 7,233 patients enrolled to the ACSIS (Acute Coronary Syndrome Israeli Survey) between 2010 and 2018, we identified 1126 eligible patients treated with prasugrel and 817 with ticagrelor. Comparison between the groups was preformed separately in ST-elevation myocardial infarction (STEMI) patients, propensity score matched (PSM) STEMI patients, and non-ST-elevation ACS (NSTE-ACS) patients. Results: In-hospital complication rates, including rates of stent thrombosis, were not significantly different between groups. In PSM STEMI patients, 30-day re-hospitalization rate (p <0.05), 30-day MACE (the composite of death, MI, stroke and urgent revascularization; p=0.006), and 1-year mortality rates (p = 0.08) were higher in the ticagrelor group compared to the prasugrel group; In NSTE-ACS patients, outcomes were not associated with drug choice. In cox regression analysis applied on the entire cohort, prasugrel was associated with lower 1-year mortality in STEMI patient but not in NSTE-ACS patients (p for interaction 0.03). Conclusions: Compared to ticagrelor, prasugrel was associated with superior clinical outcomes in STEMI patients, but not in NSTE-ACS patients.


Author(s):  
Patrick Maréchal ◽  
Julien Tridetti ◽  
Mai-Linh Nguyen ◽  
Odile Wéra ◽  
Zheshen Jiang ◽  
...  

Aims: Clinical evidence indicates that innate immune cells may contribute to the onset and outcome of acute coronary syndrome (ACS). Our prospective study aimed at analysing neutrophil phenotypes in ACS and their role in predicting 1-year major cardiovascular events. Methods: Blood neutrophil phenotypes were analysed by flow cytometry. Differential blood cell count and plasma levels of soluble markers were recorded at admission and at 6-month follow-up. Results: 108 patients categorized in chronic stable coronary artery disease (n=37), unstable angina (UA) (n=19), Non-ST-Elevation Myocardial Infarction (NSTEMI) (n=25), and ST-Elevation Myocardial Infarction (STEMI) (n=27) were included. STEMI and NSTEMI patients displayed higher neutrophil count and neutrophil-to-lymphocyte ratio (NLR) than stable and UA patients (P&lt;0.0001), which normalized at 6-month after MI. STEMI patients were characterized by elevated percentages of band cells in low-density neutrophils (P=0.007) and in high-density neutrophils (P=0.019) compared to the other patients. Multivariable logistic regression analysis revealed that plasma levels of total MPO was associated with STEMI when compared to stable (OR: 1.434; 95% CI: 1.119-1.837; P&lt;0.0001), UA (1.47; 1.146-1.886; P=0.002), and NSTEMI (1.213; 1.1-1.134; P=0.0001) patients, while increased neutrophil SSC signal intensity was associated with NSTEMI compared to stable patients (3.828; 1.033-14.184; P=0.045). Based on multivariable Cox regression analysis, elevated plasma levels of PCSK9 and low-density neutrophil percentage predicted 1-year outcome independently of cardiovascular risk factors (c-index: 0.915; IQR: 0.908-0.929). Conclusions: Changes in neutrophil phenotype are concomitant to ACS. These changes may differ between STEMI and NSTEMI. They may also contribute to ACS risk and patient outcome.


Resuscitation ◽  
2011 ◽  
Vol 82 ◽  
pp. S18-S19
Author(s):  
Bellili Sarra ◽  
Amira Feten ◽  
Souissi Sami ◽  
Ghazeli Hanen ◽  
Yahmadi Anour ◽  
...  

2014 ◽  
Vol 99 (792) ◽  
pp. 109-110
Author(s):  
María Sierra-Girón-Prieto ◽  
Gema García-Prieto ◽  
Margarita Martínez-Zaldivar-Moreno

Sign in / Sign up

Export Citation Format

Share Document